
## **Stanley Fan**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5900185/publications.pdf Version: 2024-02-01



**STANLEY FAN** 

#	Article	IF	CITATIONS
1	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Peritoneal Dialysis International, 2016, 36, 481-508.	2.3	745
2	Fluid Status in Peritoneal Dialysis Patients: The European Body Composition Monitoring (EuroBCM) Study Cohort. PLoS ONE, 2011, 6, e17148.	2.5	216
3	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 2022, 42, 110-153.	2.3	209
4	Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney International, 2000, 57, 684-690.	5.2	143
5	Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function. Kidney International, 2008, 73, 200-206.	5.2	142
6	Efficacy and Tolerability of Sevelamer Carbonate in Hyperphosphatemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1125-1130.	4.5	83
7	Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney International, 2014, 85, 151-157.	5.2	80
8	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2008, 24, 278-285.	0.7	70
9	Quality of life of caregivers and patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2008, 23, 1713-1719.	0.7	63
10	Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney International, 2003, 63, 2275-2279.	5.2	62
11	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2620-2628.	0.7	61
12	Extracellular Volume Expansion in Peritoneal Dialysis Patients. International Journal of Artificial Organs, 2012, 35, 338-345.	1.4	56
13	Single UK centre experience on the treatment of PD peritonitisantibiotic levels and outcomes. Nephrology Dialysis Transplantation, 2007, 22, 1714-1719.	0.7	54
14	Comparing automated peritoneal dialysis with continuous ambulatory peritoneal dialysis: survival and quality of life differences?. Nephrology Dialysis Transplantation, 2011, 26, 1702-1708.	0.7	49
15	Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney International, 2008, 74, 946-951.	5.2	48
16	A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrology Dialysis Transplantation, 2009, 24, 3794-3799.	0.7	47
17	Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney International, 2011, 80, 986-991.	5.2	47
18	Evaluation of a Phosphate Management Protocol to Achieve Optimum Serum Phosphate Levels in Hemodialysis Patients. , 2008, 18, 521-529.		37

2

STANLEY FAN

#	Article	IF	CITATIONS
19	Is Extracellular Volume Expansion of Peritoneal Dialysis Patients Associated with Greater Urine Output?. Blood Purification, 2011, 32, 226-231.	1.8	34
20	The Effect of Racial Origin on Total Body Water Volume in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2492-2498.	4.5	33
21	Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis. CKJ: Clinical Kidney Journal, 2019, 12, 262-268.	2.9	26
22	Comparing lung ultrasound with bioimpedance spectroscopy for evaluating hydration in peritoneal dialysis patients. Nephrology, 2015, 20, 1-5.	1.6	25
23	Can Bioimpedance Measurements of Lean and Fat Tissue Mass Replace Subjective Global Assessments in Peritoneal Dialysis Patients?. , 2015, 25, 480-487.		24
24	Encapsulating Peritoneal Sclerosis. Seminars in Nephrology, 2017, 37, 93-102.	1.6	24
25	Bisphosphonates in renal osteodystrophy. Current Opinion in Nephrology and Hypertension, 2001, 10, 581-588.	2.0	21
26	A single weekly Kt/Vurea target for peritoneal dialysis patients does not provide an equal dialysisÂdose for all. Kidney International, 2016, 90, 1342-1347.	5.2	18
27	The impact of volume overload on technique failure in incident peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 570-577.	2.9	17
28	Tackling Dialysis Burden around the World: A Global Challenge. Kidney Diseases (Basel, Switzerland), 2021, 7, 167-175.	2.5	17
29	Hydration status measured by BCM: A potential modifiable risk factor for peritonitis in patients on peritoneal dialysis. Nephrology, 2016, 21, 404-409.	1.6	16
30	The Importance of Overhydration in Determining Peritoneal Dialysis Technique Failure and Patient Survival in Anuric Patients. International Journal of Artificial Organs, 2015, 38, 575-579.	1.4	15
31	LACK OF MOTIVATION: A NEW MODIFIABLE RISK FACTOR FOR PERITONITIS IN PATIENTS UNDERGOING PERITONEAL DIALYSIS?. Journal of Renal Care, 2015, 41, 33-42.	1.2	15
32	Comparison of equations of resting and total energy expenditure in peritoneal dialysis patients using body composition measurements determined by multi-frequency bioimpedance. Clinical Nutrition, 2018, 37, 646-650.	5.0	15
33	Comparative study of diagnosis of PD peritonitis by quantitative polymerase chain reaction for bacterial DNA vs culture methods. Journal of Nephrology, 2006, 19, 45-9.	2.0	14
34	Predictors of Survival and Technique Success after Reinsertion of Peritoneal Dialysis Catheter following Severe Peritonitis. Peritoneal Dialysis International, 2007, 27, 67-73.	2.3	13
35	Race and sex: Predictors of the severity of hyperparathyroidism in peritoneal dialysis patients. Nephrology, 2006, 11, 15-20.	1.6	10
36	CORRELATION OF PERISCREEN STRIP RESULTS AND WHITE CELL COUNT IN PERITONEAL DIALYSIS PERITONITIS. Journal of Renal Care, 2010, 36, 90-95.	1.2	10

STANLEY FAN

#	Article	IF	CITATIONS
37	Therapeutic Implications of Coexisting Severe Pulmonary Hemorrhage and Pulmonary Emboli in a Case of Wegener Granulomatosis. American Journal of Kidney Diseases, 2009, 53, e5-e8.	1.9	9
38	Peritoneal Dialysis Adequacy in Elderly Patients. Peritoneal Dialysis International, 2015, 35, 635-639.	2.3	9
39	Single-dwell treatment with a low-sodium solution in hypertensive peritoneal dialysis patients. Peritoneal Dialysis International, 2020, 40, 446-454.	2.3	9
40	Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels?. BMC Nephrology, 2011, 12, 55.	1.8	8
41	Pitfalls in the measurement of skin auto-fluorescence to determine tissue advanced glycosylation content in haemodialysis patients. Nephrology, 2013, 18, n/a-n/a.	1.6	8
42	Performance of Gram Stains and 3 Culture Methods in the Analysis of Peritoneal Dialysis Fluid. Peritoneal Dialysis International, 2019, 39, 190-192.	2.3	8
43	Successful Use of Continuous Ambulatory Peritoneal Dialysis in 2 Adults With a Gastrostomy. American Journal of Kidney Diseases, 2014, 64, 316-317.	1.9	7
44	Peritoneal dialysis in patients with failed kidney transplant: Single centre experience. Nephrology, 2018, 23, 162-168.	1.6	7
45	Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study. Clinical Nephrology, 2015, 84 (2015), 274-279.	0.7	7
46	Does Loss of Residual Renal Function Lead to Increased Volume Overload and Hypertension in Peritoneal Dialysis Patients?. Peritoneal Dialysis International, 2015, 35, 753-755.	2.3	6
47	Optimizing Peritoneal Dialysis Catheter Placement by Lateral Abdomen X-Ray. Peritoneal Dialysis International, 2015, 35, 760-762.	2.3	5
48	Comparison of skin autofluorescence, a marker of tissue advanced glycation endâ€products in peritoneal dialysis patients using standard and biocompatible glucose containing peritoneal dialysates. Nephrology, 2019, 24, 835-840.	1.6	5
49	Accelerated Decline of GFR in Diabetic Nephropathy Predicted by Interferon Release Assay to Tuberculosis Antigens. Nephron Clinical Practice, 2011, 117, c266-c269.	2.3	4
50	Persistent colonization of exit site is associated with modality failure in peritoneal dialysis. Peritoneal Dialysis International, 2022, 42, 96-99.	2.3	3
51	MP487HOW TO OVERCOME BARRIERS AND START UP NEW PERITONEAL DIALYSIS PROGRAMS - EXPERIENCE FROM NEPAL. Nephrology Dialysis Transplantation, 2016, 31, i503-i503.	0.7	2
52	Relationship between sodium removal, hydration and outcomes in peritoneal dialysis patients. Nephrology, 2021, 26, 676-683.	1.6	1
53	A case of paradoxical reaction after treatment of generalized tuberculous lymphadenopathy in a peritoneal dialysis patient. SAGE Open Medical Case Reports, 2022, 10, 2050313X2210848.	0.3	1
54	FP599PERITONEAL DIALYSIS TECHNIQUE FAILURE AFTER LOSS OF RESIDUAL RENAL FUNCTION. Nephrology Dialysis Transplantation, 2015, 30, iii272-iii273.	0.7	0

#	Article	IF	CITATIONS
55	Response to Letter "Gram Stain of Peritoneal Dialysis Fluid: The Potential of Direct Policy-Determining Importance in Early Diagnosis of Fungal Peritonitisâ€: Peritoneal Dialysis International, 2019, 39, 575-575.	2.3	Ο
56	Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids. Artificial Organs, 2021, 45, 88-94.	1.9	0